Efficacy and Safety of TAK-583 in Subjects With Diabetic Peripheral Neuropathy

Diabetic Neuropathies Clinical Trial

Official title:

A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Study to Evaluate the Efficacy and Safety of 3 Doses of TAK-583 in Subjects With Mild to Moderate Diabetic Peripheral Neuropathy

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00760955
• Other study ID #: 01-06-TL-583-006
• Secondary ID: U1111-1129-7781
• Status: Completed
• Phase: Phase 2
• First received: September 24, 2008
• Last updated: June 20, 2016
• Start date: September 2006
• Est. completion date: February 2008

Study information

• Verified date: June 2016
• Source: Takeda
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine the safety and effectiveness of TAK-583, once daily (QD), in the treatment of neuropathy caused by diabetes mellitus.

Description:

Diabetic polyneuropathy is a frequent complication in individuals with type 1 and 2 diabetes mellitus, and can result in progressive functional and structural deficits in both somatic and autonomic nerves. Diabetic polyneuropathy is characterized by degenerative changes in nerve fibers resulting in progressive functional and structural deficits in both somatic and autonomic nerves.

TAK-583 is a synthetic compound currently under development for the treatment of diabetic polyneuropathy. The purpose of this study is to evaluate the safety and efficacy of TAK-583 for the treatment of mild to moderate diabetic polyneuropathy in subjects with type 1 or type 2 diabetes mellitus. Study participation is anticipated to be about 8 months.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 338
• Est. completion date: February 2008
• Est. primary completion date: February 2008
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Female subjects must be post-menopausal or status post documented hysterectomy and bilateral oophorectomy.

• Has fasting clinical laboratory evaluations within the normal reference range for the testing laboratory, or if not, the results must be deemed not clinically significant by the investigator prior to randomization.

• Has Type 1 or type 2 diabetes, as defined by World Health Organization Criteria.

• Has mild to Moderate Diabetic Peripheral Neuropathy defined as:

• Confirmed abnormality of at least two nerve conduction velocity parameters as defined by the Neurological Core Laboratory.

• Sural sensory nerve potential amplitude greater than or equal to 1 µV (microvolt).

• Has glycosylated hemoglobin less than or equal to 10%.

• Is on stable pain medications for at least 3 weeks prior to randomization, if applicable.

• Has a glomerular filtration rate calculated by Modification of Diet in Renal Disease of greater than or equal to 45 mL/min/ body surface area.

• Spot albumin/creatinine ratio of less than 300 mg/g creatinine or 33.9 mg/mmol creatinine.

• Has acceptable clinical laboratory test results as defined by:

• Hemoglobin Greater than or equal to 9.0 g/dL or 5.58 mmol/L

• Thyroid stimulating hormone Within normal limits

• Free T4 index Within normal limits

• B12 level Within normal limits

• Is willing to follow an American Diabetes Association or similar recommended dietary regimen.

Exclusion Criteria

• Individuals with a history of other neuropathies due to causes other than diabetes such as alcohol abuse, liver or renal disease, uremia, toxic exposure, genetic factors, autoimmune disorders, inflammatory demyelinating diseases, monoclonal gammopathies; or endocrine, metabolic or nutritional disorders.

• Has clinical or electrophysiologic evidence of bilateral carpal tunnel syndrome.

• Has a significant skin abnormality or ulcerative changes in their lower extremities that may interfere with the performance of the study related procedures.

• Has a body mass index greater than 45 kg/m2.

• Participants with uncontrolled hypertension or a systolic blood pressure greater than 160 mm Hg or a diastolic blood pressure of greater than 95 mm Hg.

• Has a history of myocardial infarction, coronary angioplasty or bypass graft, unstable angina pectoris, transient ischemic attacks, clinically significant abnormal electrocardiograms, New York Heart Association Functional Classification III or IV, or documented cerebrovascular accident.

• Has a marked baseline prolongation of QT/QTc interval (e.g., repeated demonstration of a QTc interval greater than 450 milliseconds).

• Has a history of additional risk factors for Torsades de pointes.

• Is required to take or intends to continue taking any disallowed medication, any prescription medication, herbal treatment or over-the counter medication that may interfere with evaluation of the study medication, including:

• Medications that prolong the QT/QTc interval.

• Lipoic acid.

• Linolenic acid (primrose oil).

• Inositol.

• Topiramate.

• Acetyl-L-Carnitine.

• Nerve growth factors.

• Capsaicin.

• CYP3A4 inhibitors (amiodarone, diltiazem, Verapamil)

• HIV protease inhibitors

• Itraconazole

• Ketoconazole

• macrolide antibiotics

• CYP 3A4 inducers

• Has an alanine aminotransferase level of greater than 1.5 times upper limit of normal, active liver disease or jaundice or Total bilirubin greater than 1.2 times upper limit of normal.

• Has a 12-hour urinary cortisol test greater than 264 nmol/night (95.6 mcg/night) at screening.

• Has clinically significant (as determined by the investigator) or unstable:

pulmonary, gastrointestinal, hepatic, hematologic, musculoskeletal, osteoporosis, osteopenia, or endocrine (other than diabetes mellitus or stably treated hypothyroidism) diseases.

• Has a previous history of cancer that has not been in remission for at least 5 years prior to the first dose of study drug.

• Has any other serious disease or condition at screening or at randomization that might affect life expectancy or make it difficult to successfully manage and follow the subjects according to the protocol.

• Has a history of drug abuse or a history of alcohol abuse within the past 2 years.

• Has a known hypersensitivity to a compound related to TAK-583.

• Is currently participating in another investigational study or has participated in an investigational study within the past 30 days.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Diabetic Neuropathies
• Peripheral Nervous System Diseases

Intervention

Drug:
• TAK-583
TAK-583 5 mg, tablets, orally, once daily for up to 6 months.
• TAK-583
TAK-583 50 mg, tablets, orally, once daily for up to 6 months.
• TAK-583
TAK-583 100 mg, tablets, orally, once daily for up to 6 months.
• Placebo
TAK-583 placebo-matching tablets, orally, once daily for up to 6 months.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Takeda

Countries where clinical trial is conducted

United States,  Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change from Baseline for a composite measure of Maximal Nerve Conduction Velocity of the Peroneal and Median Motor Nerves and the Median and Sural Sensory Nerves.		Month 6 or Final Visit	No
Secondary	Change from Baseline in Electrophysiological Parameters for Individual Nerves.		Month 6 or Final Visit	No
Secondary	Change from Baseline in Sensory Sub-Composite and Motor Sub-Composite Scores.		Months 3 and 6 or Final Visit	No
Secondary	Change in Vibration Perception Threshold.		Months 3 and 6 or Final Visit	No
Secondary	Change in Pain Scores.		Months 1, 2, 3, 4, 5, and 6 or Final Visit	No
Secondary	Change in Neurological Examination Score.		Months 3 and 6 or Final Visit	No
Secondary	Change in Quality of Life Index Score.		Months 1, 2, 3, 4, 5, and 6 or Final Visit	No
Secondary	Change in glycosylated hemoglobin.		Months 3 and 6 or Final Visit	No
Secondary	Change in fasting plasma glucose.		Months 3 and 6 or Final Visit	No
Secondary	Change in fasting insulin.		Months 3 and 6 or Final Visit	No
Secondary	Change in Fasting C-peptide.		Months 3 and 6 or Final Visit	No